Companies
GSK
PharmaceuticalsLondon, United KingdomGSK66,841 employees
WorkHush has 1 source-backed update on GSK workforce changes since October 2026. The latest, added October 14, 2026: Up to 1,217 roles at risk in Belgium in R&D, manufacturing, support (confirmed reduction). Read it with sources ›
More about GSK
Drugmaker that develops and sells vaccines and specialty medicines for infectious diseases, HIV, cancer and respiratory conditions
Revenue
£32.7B
Fiscal 2025, up 4.1%
Employees
66,841
As of December 2025
Stock
GSK
New York Stock Exchange
Headquarters
London, United Kingdom
CEO
Luke Miels
Since January 2026
BrandsShingrix, Arexvy, Trelegy, Nucala, Dovato, ViiV Healthcare
Current strategyReallocating resources to specialty medicines and oncology deals ahead of HIV patent losses from 2028, targeting £40B in annual sales by 2031
Recent workforce changesThree-year plan announced in July 2026 to save about £1.9B a year, including unspecified job cuts and leaving its Stevenage research site
CompetitorsAstraZeneca, Pfizer, Sanofi
Related companiesAstraZenecaPfizerSanofi
Checked October 11, 2026 · Sources: sec.gov, biopharmadive.com
No one has posted about GSK yet. Be the first to post ›
Follow GSK in a feed reader, no account needed: RSS feed